Peter Miller, MD, PhD

This interview in the latest issue of The Respiratory Report features Peter Miller, MD, PhD, discussing the potential role of CH in developing COPD.

Uncovering the Link Between Clonal Hematopoiesis and COPD

Recent research has uncovered a potential link between clonal hematopoiesis and an increased risk of chronic obstructive pulmonary disease (COPD). This association was further explored in new research led by Peter Miller, MD, PhD, Assistant Professor of Medicine at Massachusetts General Hospital and Harvard Medical School.

 that is powered by the American Lung Association Research Institute, on his team’s current research in this area.

In a cohort study of 50,000 individuals, his team found that people with CH were more likely to develop COPD, even after adjusting for age and smoking history. Interestingly, cigarette smoke not only increases COPD risk but also appears to drive the development of CH, creating a potential feedback loop: smoke exposure promotes CH, which in turn heightens inflammatory responses that may exacerbate or even trigger COPD. This hypothesis was further supported by mouse model studies in Miller's lab which found that mice with CH mutations exposed to cigarette smoke developed more emphysema than controls.

"What we're trying to do is really refine the association in the human genetics of how these risk factors play together, and potentially take advantage of different variations in DNA amongst that are different between different people to understand what other factors may be playing a role in these in these risks," Miller said.

To learn more about Miller's research, view the interview above or read his contribution to the second issue of The Respiratory Report here:

Uncovering the Link Between Clonal Hematopoiesis and Chronic Obstructive Pulmonary Disease

Videos

This interview in the latest issue of The Respiratory Report features Peter Miller, MD, PhD, discussing the potential role of CH in developing COPD.



Peter Miller, MD, PhD, Assistant Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, is conducting groundbreaking research to elucidate the role of clonal hematopoiesis (CH) in chronic obstructive pulmonary disease (COPD), with a particular emphasis on somatic mutations in the 

 gene. COPD, a progressive lung disease resulting in airflow limitation, remains a leading cause of morbidity and mortality and is the fourth leading cause of death in the United States.

Though advancing treatment options have improved outcomes in individuals with COPD, prevention and risk stratification for both disease onset and progression remain unmet needs. Efforts to better define factors that contribute to the development and progression of COPD are therefore needed. The pathogenic drivers of COPD, which include both adaptive and innate immune signaling and characterized by enhanced inflammation, remain incompletely understood.

 Risk factors for developing COPD can be broadly categorized as age-related, environmental, and genetic. The strongest environmental risk factor remains cumulative cigarette smoke(CS) exposure.

 The genetic contributors for development of COPD have been almost exclusively related to germline risk, including monogenic risk alleles, such as alpha-1 antitrypsin deficiency, and polygenic risk contribution.

Recent investigations led by Dr. Miller have uncovered a previously unrecognized association between clonal hematopoiesis—characterized by somatic mutations in hematopoietic stem cells—and an increased risk of developing COPD, independent of conventional risk factors such as cigarette smoke exposure and inherited genetic variants.

CH is a very common, age-associated condition, with up to 10% of individuals by the age of 60-70 having large mutant clones in the peripheral blood.

, the third most frequently mutated gene in CH, have been identified as significant contributors to inflammatory pathways involved in COPD.

 mutations disrupt normal chromatin remodeling and gene regulation, promoting inflammatory responses in blood cells, notably macrophages. Dr. Miller's preliminary data strongly suggest that individuals harboring 

 mutations exhibit higher susceptibility to COPD.

To rigorously test and expand upon these findings, Dr. Miller's proposal integrates 2 comprehensive aims designed to address critical gaps in current knowledge. First, through extensive genetic epidemiological studies involving approximately 500,000 participants from prominent biobanks such as the UK Biobank, TOPMed, and Massachusetts General Brigham, the research will systematically quantify the association between 

-mutant CH and COPD. This analysis will pinpoint genetic modifiers, particularly inflammatory gene variants, which may intensify disease risk. The research further seeks to characterize distinct clinical COPD phenotypes associated with 

 mutations, such as frequency and severity of exacerbations and specific radiological manifestations of emphysema.

Second, leveraging cutting-edge mouse models, Dr. Miller's team will experimentally confirm these epidemiological findings and delve deeper into the mechanistic roles of 

 mutations in driving COPD pathogenesis. By engineering mice to express 

 mutations selectively in hematopoietic cells and subsequently exposing them to cigarette smoke, the team aims to closely mimic the human disease environment. Detailed analyses of emphysema severity, inflammatory responses, and cellular changes within lung tissues will be conducted using advanced methodologies like single-cell RNA sequencing. Furthermore, the therapeutic potential of inflammatory blockade will be rigorously evaluated, potentially offering innovative avenues for COPD management.

This integrated research approach uniquely positions Dr. Miller's work at the forefront of pulmonary medicine, bridging disciplines of hematology and pulmonology while utilizing state-of-the-art genetic and genomic tools to uncover novel inflammatory mechanisms in COPD. Outcomes from this study hold considerable promise for reshaping our understanding of COPD, significantly enhancing risk prediction, and opening pathways to groundbreaking preventative and therapeutic interventions.

Miller has no relevant disclosures to report.

1.Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. 

. May 2013;143(5):1395-1406. doi:10.1378/chest.12-1135

2.Kochanek KD, Murphy S, Xu J, Arias E. Mortality in the United States, 2016. 

3.Caramori G, Adcock IM, Di Stefano A, Chung KF. Cytokine inhibition in the treatment of COPD. 

. 2014;9:397-412. doi:10.2147/COPD.S42544

4.Hubeau C, Kubera JE, Masek-Hammerman K, Williams CM. Interleukin-6 neutralization alleviates pulmonary inflammation in mice exposed to cigarette smoke and poly(I:C). 

. Nov 2013;125(10):483-93. doi:10.1042/CS20130110

5.Grubek-Jaworska H, Paplinska M, Hermanowicz-Salamon J, et al. IL-6 and IL-13 in induced sputum of COPD and asthma patients: correlation with respiratory tests. 

. 2012;84(2):101-7. doi:10.1159/000334900

6.Hobbs BD, de Jong K, Lamontagne M, et al. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. 

. Mar 2017;49(3):426-432. doi:10.1038/ng.3752

7.Sakornsakolpat P, Prokopenko D, Lamontagne M, et al. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. 

. Mar 2019;51(3):494-505. doi:10.1038/s41588-018-0342-2

8.Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. 

. Jul 2020;8(7):696-708. doi:10.1016/S2213-2600(20)30101-6

9.Miller PG, Qiao D, Rojas-Quintero J, et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. 

. Jan 20 2022;139(3):357-368. doi:10.1182/blood.2021013531

10.Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. 

. Dec 25 2014;371(26):2488-98. doi:10.1056/NEJMoa1408617

11.Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. 

. Jan 2017;17(1):5-19. doi:10.1038/nrc.2016.112

12.Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. 

. Aug 14 2012;22(2):180-93. doi:10.1016/j.ccr.2012.06.032

13.Fujino T, Goyama S, Sugiura Y, et al. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. 

. Mar 23 2021;12(1):1826. doi:10.1038/s41467-021-22053-y

14.Min KD, Polizio AH, Kour A, Thel MC, Walsh K. Experimental ASXL1-Mediated Clonal Hematopoiesis Promotes Inflammation and Accelerates Heart Failure. 

. Oct 4 2022;11(19):e026154. doi:10.1161/JAHA.122.026154

Articles

Dr. Peter Miller is pioneering research on the role of clonal hematopoiesis (CH) in COPD, focusing on ASXL1 gene mutations. COPD, a major cause of morbidity and mortality, lacks effective prevention and risk stratification strategies. Dr. Miller's work reveals a link between CH and COPD risk, independent of traditional factors like smoking. His research involves large-scale genetic studies and mouse models to explore ASXL1's impact on COPD pathogenesis. This work aims to enhance understanding of COPD, improve risk prediction, and develop novel therapeutic interventions.

Peter Miller, MD, PhD, from Massachusetts General Hospital and Harvard Medical School, is working to further uncover the role of clonal hematopoeisis in COPD.